The assessment discusses fifty eight peptides in several clinical phases, indicating a strong pipeline of peptide therapies targeting PPIs. Any opportunity conflicts of curiosity, which include funding from pharmaceutical organizations or personal investments in relevant industries, are completely disclosed in the research publications. This disclosure is critical to protect integrity https://friedensreichq840jug9.wikibyby.com/user